EmblemHealth files amended US antitrust claims against Alexion over Soliris
MLex Summary: EmblemHealth filed an amended US complaint accusing Alexion Pharmaceuticals of unlawfully delaying the introduction of biosimilar competition for eculizumab, a humanized monoclonal antibody that treats a range of rare...To view the full article, register now.
Already a subscriber? Click here to view full article